

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

(Dollars in Millions Except Per Share Data)	2023		
	Q1	Q2	SIX MONTHS
Net Earnings/(loss) from Continuing Operations, after tax - as reported	\$ (491)	5,376	4,885
<i>Pre-tax Adjustments</i>			
Intangible Asset Amortization expense	1,122	1,130	2,252
Litigation related	6,900	137	7,037
IPR&D impairments	49	0	49
Restructuring related	130	145	275
Acquisition, integration and divestiture related	42	38	80
(Gains)/losses on securities	72	(1)	71
Medical Device Regulation	64	85	149
COVID-19 Vaccine related costs	444	165	609
<i>Tax Adjustments</i>			
Tax impact on special item adjustments	(1,980)	(307)	(2,287)
Consumer Health separation tax related costs	11	(17)	(6)
Tax legislation and other tax related	(23)	(21)	(44)
Adjusted Net Earnings from continuing operations, after tax	\$ 6,340	6,730	13,070
Average shares outstanding (Diluted)	2,634.3	2,625.7	2,630.7
Adjusted net earnings per share from continuing operations (Diluted)	\$ 2.41	2.56	4.97